Open Access
Feature Article

Liraglutide: for obesity, not just type 2 diabetes

Open Access
Feature Article

Liraglutide: for obesity, not just type 2 diabetes

Arianne N Sweeting, Ian D. Caterson

Figures

© PICTURE-FACTORY/ STOCK.ADOBE.COM MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY.
© PICTURE-FACTORY/ STOCK.ADOBE.COM MODEL USED FOR ILLUSTRATIVE PURPOSES ONLY.
Dr Sweeting is an Endocrinologist at Royal Prince Alfred Hospital, Sydney; and a Researcher at the Boden Collaboration of Obesity, Nutrition, Exercise and Eating Disorders, The University of Sydney, Sydney. Professor Caterson is an Endocrinologist at Royal Prince Alfred Hospital, Sydney; and Boden Professor of Human Nutrition at the Boden Collaboration of Obesity, Nutrition, Exercise and Eating Disorders, The University of Sydney, Sydney, NSW.

 

Advertisement

References

1.    Van Can J, Jensen CB, Flint A, Blaak EE,  Saris WHM. Effects of once daily GLP-1 analog liraglutide on gastric emptying, glycaemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-793.
2.    Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes (Lond) 2001; 25: 781-792.
3.    Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332. 
4.    Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
5.    Sisley S, Gutierrez-Aguilar R, Scott M, D’Alessio DA, Sandoval DA, Seeley RJ. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest 2014; 124: 2456-2463.
6.    Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473-4488.
7.    Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
8.    Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
9.    Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37: 1443-1451.
10.    Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
11.    Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843-854.
12.    Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22. 
13.    Marso SP, Daniels GH, Brown-Frandsen K,  et al. Liraglutide and cardiovascular outcomes  in type 2 diabetes. N Engl J Med 2016; 375:  311-322.
14.    Li Z, Maglione M, Tu W, Mojica W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 535-546. 
15.    Sweeting A, Hocking S, Markovic T. Pharmacotherapy for the treatment of obesity.  Mol Cell Endocrinol 2015; 418 Pt 2: 173-183.
16.    US Food and Drug Administration. Medication guide Saxenda® (sax-end-ah) (liraglutide  [rDNA origin]) injection. Available online at:  www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf  (accessed August 2020). 
17.    US Food and Drug Administration. FDA approves weight-management drug Saxenda [press release]. Available online at: www.saxenda.com (accessed August 2020).